Search
An Australian-first study, funded by Perth Children's Hospital Foundation, demonstrating the effectiveness of a new immunisation against respiratory syncytial virus (RSV) for babies found it to be almost 90 per cent effective in reducing hospitalisation rates.
Alarming statistics laying bare the social emotional wellbeing and mental health challenges facing Aboriginal and Torres Strait Islander LGBTQA+ youth are driving a multi-partner program to provide them with greater support.
Research
A malaria seasonality dataset for sub-Saharan AfricaMalaria imposes a significant global health burden and remains a major cause of child mortality in sub-Saharan Africa. In many countries, malaria transmission varies seasonally. The use of seasonally-deployed interventions is expanding, and the effectiveness of these control measures hinges on quantitative and geographically-specific characterisations of malaria seasonality.
Research
Rethinking a hybrid malaria chemoprevention delivery strategy for children in sub-perennial settings: a modelling study integrating age- and seasonally-targeted deliveryThe World Health Organization recommends perennial malaria chemoprevention (PMC), generally using sulfadoxine-pyrimethamine (SP) to children at high risk of severe Plasmodium falciparum malaria. Currently, PMC is given up to age two in perennial transmission settings. However, no recommendation exists for perennial settings with seasonal variation in transmission intensity, recently categorized as 'sub-perennial'.
Research
Value profile for Malaria vaccines and monoclonal antibodies1Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decades of this century, scale-up of a range of tools was associated with significant reductions in malaria mortality in the primary risk group, young African children.
Research
SHIP CT: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial.SHIP-CT, led by Professor Stephen Stick, Director of the Wal-yan Respiratory Research Centre at The Kids, is a unique study in preschool-aged children (from 3-6 years of age) with CF using images of the lung from chest CT scans as the main outcome measure.
We rely on the support of donors & fundraisers to be able to conduct the life changing pediatric research we do on a day-to-day basis. Will you help?
Research
Precision pathways for young children at risk of Neurodevelopmental Disorders: Early identification and adaptive intervention starting from the prenatal periodAmy Andrew Carol Deborah Gail Helen Jenny Kandice Martyn Videos Finlay-Jones Whitehouse Watch and listen to Andrew Bower Strickland Alvares Leonard
Research
ORIGINS of Neurodevelopmental Risk and ResilienceThis project aims to better understand the early genetic and environmental factors that the developing brain during a child’s first five years of life.
News & Events
Vaccination seminar presentationsOn Monday May 30, The Kids Research Institute Australia held a free public seminar on vaccination, hearing from paediatricians and infectious disease researchers.